LB17. Age-related differences in influenza type/subtype among patients hospitalized with influenza, FluSurv-NET—2017–2018
Session: Oral Abstract Session: Late Breaker Oral Abstracts: Influenza and Vaccines
Saturday, October 6, 2018: 11:00 AM
Room: S 152-154

Background: The 2017-18 influenza season had the highest rates of influenza hospitalizations since the 2009 H1N1 pandemic. We used data from the Influenza Hospitalization Surveillance Network (FluSurv-NET) to identify unique characteristics of the 2017–18 season.

Methods: We included all patients residing within a FluSurv-NET catchment area, and hospitalized with laboratory-confirmed influenza during 2017-18. We used multiple imputation, including age, surveillance site, and month of hospital admission as predictors, to impute influenza A subtype for 40–64% of cases across seasons with an unknown subtype. We calculated influenza hospitalization rates by type/subtype per 100,000 population. We compared 2017-18 rates to rates during 4 prior seasons: 2016-17, 2015-16, 2014-15, and 2013-14.  

Results: The overall unadjusted hospitalization rates per 100,000 population varied from 31.5 during 2015–16 to 105.1 during 2017-18. After imputing A subtype, the 2017-18 season had the highest rates observed for H3N2 (62.8) and B (28.5) than in any previous season, and the 3rd highest rate of H1N1 (13.5) (Figure 1A). During 2017-18, rates in adult ≥65 years peaked 3 weeks before they peaked in children 0-4 years. In contrast, during the 4 prior seasons, rates in adults ≥65 years peaked during the same week or 1 week after they peaked in children 0-4 years. During 2017-18, the distribution of influenza type/subtypes varied significantly by age group (p <0.0001); for example, the proportion of cases with H1N1 ranged from 19 to 29% in those <65 years to only 7% in those ≥65 years. During 2017-18, H1N1 (the non-predominant A virus) contributed >25% of A cases across all age groups (except ≥65 years) versus all prior seasons where the non-predominant A virus contributed <10% of A cases across all age groups (except ≥65 years) (Figure 1B-F).

Conclusions: Several unique characteristics may have contributed to the high hospitalization rates observed during 2017-18. Rates in older adults, who were predominantly infected with H3N2, peaked several weeks prior to children in contrast to prior seasons.  Higher overall rates of H3N2 and B were observed in 2017-18 compared to these prior seasons and substantial H1N1 co-circulation also occurred with marked variability by age group.  

 

 

Shikha Garg, MD, MPH1, Alissa O'Halloran, MSPH1, Charisse Nitura Cummings, MPH1, Evan J. Anderson, MD2, Nisha Alden, MPH3, Nancy M. Bennett, MD4, Laurie Billing, MPH5, Shua J. Chai, MD, MPH6, Sue Kim, MPH7, Ruth Lynfield, MD, FIDSA8, Alison Muse, MPH9, Andrea Price, LPN10, Patricia Ryan, MS11, H. Keipp Talbot, MD, MPH12, Salina Torres, MPH13, Kimberly Yousey-Hindes, MPH, CPH14, Ann Thomas, MD, MPH15 and Carrie Reed, DSc, MPH1, (1)Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA, (2)Emerging Infections Program, Atlanta Veterans Affairs Medical Center, Atlanta, GA, (3)Colorado Department of Public Health and Environment, Denver, CO, (4)Emerging Infections Program, Rochester, NY, (5)Ohio Department of Health, Columbus, OH, (6)Assigned to the California Department of Public Health, US Centers for Disease Control (CDC), Richmond, CA, (7)Michigan Department of Health and Human Services, Lansing, MI, (8)Minnesota Department of Health, St. Paul, MN, (9)New York State Department of Health, Albany, NY, (10)Salt Lake County Health Department, Salt Lake City, UT, (11)MD Dept Health Mental Hygiene, Baltimore, MD, (12)Infectious Diseases, Vanderbilt University Medical Center, Nashville, TN, (13)New Mexico Department of Health, Albuqurque, NM, (14)Connecticut Emerging Infections Program, Yale School of Public Health, New Haven, CT, (15)Oregon Public Health Division, Portland, OR

Disclosures:

S. Garg, None

A. O'Halloran, None

C. Nitura Cummings, None

E. J. Anderson, NovaVax: Grant Investigator , Research grant . Pfizer: Grant Investigator , Research grant . AbbVie: Consultant , Consulting fee . MedImmune: Investigator , Research support . PaxVax: Investigator , Research support . Micron: Investigator , Research support .

N. Alden, None

N. M. Bennett, None

L. Billing, None

S. J. Chai, None

S. Kim, None

R. Lynfield, None

A. Muse, None

A. Price, None

P. Ryan, None

H. K. Talbot, Sanofi Pasteur: Investigator , Research grant . Gilead: Investigator , Research grant . MedImmune: Investigator , Research grant . Vaxinnate: Safety Board , none . Seqirus: Safety Board , none .

S. Torres, None

K. Yousey-Hindes, None

A. Thomas, None

C. Reed, None

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.